Breast Cancer Research and Treatment

, Volume 14, Issue 2, pp 201–206 | Cite as

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

  • S. Lundgren
  • S. Gundersen
  • R. Klepp
  • P. E. Lønning
  • E. Lund
  • S. Kvinnsland
Report

Summary

In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment>8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).

Key words

advanced breast cancer second-line endocrine therapy megestrol acetate aminoglutethimide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beatson GT: Oophorectomy in advanced breast cancer in young women. Lancet II: 104, 1896Google Scholar
  2. 2.
    Macaulay V, Smith IE: Advanced breast cancer. In: ML Slevin, MJ Staquet (eds) Randomized trials in cancer. A critical review by sites. Vol 15. Raven Press, New York, 1986, pp 273–357Google Scholar
  3. 3.
    Cole MP, Jones CTA, Todd IDA: A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 146474. Br J Cancer 25: 270–275, 1971PubMedGoogle Scholar
  4. 4.
    Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal women with advanced breast cancer. J Clin Oncol 4: 1236–1240, 1986Google Scholar
  5. 5.
    Stoll BA: Combination endocrine therapy — concurrent or sequential? In: BA Stoll (ed) Endocrine management of cancer. 2. Contemporary therapy. Karger, Basel, pp 80–101, 1988Google Scholar
  6. 6.
    Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher AE: Aminoglutethimide as treatment of postmenopausal women with advanced breast cancer. Ann Int Med 96: 94–101, 1982PubMedGoogle Scholar
  7. 7.
    Sedlacek SM, Horwitz KB: The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44: 467–484, 1984PubMedGoogle Scholar
  8. 8.
    Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298, 1977PubMedGoogle Scholar
  9. 9.
    Kvinnsland S, Lønning PE, Dahl O: Treatment of breast carcinoma with aminoglutethimide. Acta Radiologica Oncologica 23: 421–424, 1984Google Scholar
  10. 10.
    Thorsen T: Occupied and unoccupied nuclear oestradiol receptor in human breast tumours: Relation to oestradiol and progesterone cytosol receptors. J Steroid Biochem 10: 661–668, 1979PubMedGoogle Scholar
  11. 11.
    Smith IE: Decision making in palliative therapy. In: BA Stoll (ed) Breast cancer. Treatment and prognosis. Blackwell Scientific Publications, Oxford, pp 86–97, 1986Google Scholar
  12. 12.
    Paterson AHG: Systemic therapy — prolonged survival or growth control. Ibid, pp 29–44, 1986Google Scholar
  13. 13.
    Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. JNCI 80: 1147–1151, 1988PubMedGoogle Scholar
  14. 14.
    Wander HE, Kleeberg UR, Gärtner E, Hartlapp J, Scherpe A, Bönisch E, Nagel GA: Megestrolazetat versus Medroxyprogesteroneazetat in der Behandlung metastasierender Mammakarzinome. Zwischenbereicht einer multizenrischen Phase-III-studie. Onkologie 10: 104–106, 1987PubMedGoogle Scholar
  15. 15.
    Morgan LR: Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol XII (suppl 1): 43–47, 1985Google Scholar
  16. 16.
    Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Stuart JJ, Richards II F, White DR, Zekan PJ, Spurr CL, Pope E, Case D, Morgan T, Wells B: Megestrol acetate v tamoxifen in advanced breast cancer: A phase III trial of the Piedmont Oncology Association (POA). Semin Oncol XII (Suppl 1): 55–61, 1985Google Scholar
  17. 17.
    van Veelen H, Willemse PHB, Tjabbes T, Schweitzer MJH, Sleijfer DT: Oral high-dose medroxyprogesterone acetate versus tamoxifen. Cancer 58: 7–13, 1986PubMedGoogle Scholar
  18. 18.
    Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432–1434, 1981Google Scholar
  19. 19.
    Harris AL, Cantwell BMJ, Sainsbury JR, Needham G, Evans RGB, Dawes PJDK, Wilson R, Farndon J: Lowdose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. Breast Cancer Res Treat (Suppl) 7: 41–44, 1986Google Scholar
  20. 20.
    Lønning PE, Kvinnsland S: Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35: 685–710, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • S. Lundgren
    • 1
  • S. Gundersen
    • 2
  • R. Klepp
    • 3
  • P. E. Lønning
    • 1
  • E. Lund
    • 2
  • S. Kvinnsland
    • 1
    • 3
  1. 1.Department of Medical Oncology and RadiotherapyUniversity of BergenNorway
  2. 2.Department of Medical Oncology and RadiotherapyThe Norwegian Radium HospitalMontebelloNorway
  3. 3.Department of Medical Oncology and RadiotherapyThe Regional and University Hospital in TrondheimTrondheimNorway

Personalised recommendations